secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRA LIFESCIENCES HOLDINGS CORP (IART)
CIK:        0000917520
Form:       8-K
Filed at:   2025-05-05T23:59:59+00:00
Accession:  0000917520-25-000038
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integra LifeSciences Q1 2025: Adj EPS $0.41 vs $0.55 YoY; organic revenue down 3.5%
--------------------------------------------------------------------------------

- Revenue of $382.7M up 3.7% reported but down 3.5% organic; GAAP net loss $(0.33)/share vs $(0.04).
- Adjusted EPS $0.41 vs $0.55 prior year; adjusted gross margin 62.2% vs 64.4%.
- Codman Specialty Surgical organic revenue -1.1%; Tissue Technologies organic -9.1%.
- Full-year 2025 revenue reaffirmed $1.65B-$1.715B; adj EPS guidance reduced to $2.19-$2.29 (incl $(0.22) tariff impact).
- Q2 2025 guidance: revenue $390M-$400M, adj EPS $0.40-$0.45; operating cash flow negative $(11.3)M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/917520/000091752025000038/0000917520-25-000038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/917520/000091752025000038/iart-20250505.htm
  HTML page:      https://secwatch.observer/filing/0000917520-25-000038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer